Cannabinoid CB1 Receptor Antagonists Attenuate Cocaine's Rewarding Effects: Experiments with Self-Administration and Brain-Stimulation Reward in Rats
- 29 August 2007
- journal article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 33 (7) , 1735-1745
Abstract
Previous studies suggest that cannabinoid CB1 receptors do not appear to be involved in cocaine's rewarding effects, as assessed by the use of SR141716A, a prototypic CB1 receptor antagonist and CB1-knockout mice. In the present study, we found that blockade of CB1 receptors by AM 251 (1–10 mg/kg), a novel CB1 receptor antagonist, dose-dependently lowered (by 30–70%) the break point for cocaine self-administration under a progressive-ratio (PR) reinforcement schedule in rats. The same doses of SR141716 (freebase form) maximally lowered the break point by 35%, which did not reach statistical significance. Neither AM 251 nor SR141716 altered cocaine self-administration under a fixed-ratio (FR2) reinforcement schedule. AM 251 (0.1–3 mg/kg) also significantly and dose-dependently inhibited (by 25–90%) cocaine-enhanced brain stimulation reward (BSR), while SR141716 attenuated cocaine's BSR-enhancing effect only at 3 mg/kg (by 40%). When the dose was increased to 10 or 20 mg/kg, both AM 251 and SR141716 became less effective, with AM 251 only partially inhibiting cocaine-enhanced BSR and PR cocaine self-administration, and SR141716 having no effect. AM 251 alone, at all doses tested, had no effect on BSR, while high doses of SR141716 alone significantly inhibited BSR. These data suggest that blockade of CB1 receptors by relatively low doses of AM 251 dose-dependently inhibits cocaine's rewarding effects, whereas SR141716 is largely ineffective, as assessed by both PR cocaine self-administration and BSR. Thus, AM 251 or other more potent CB1 receptor antagonists deserve further study as potentially effective anti-cocaine medications.Keywords
This publication has 68 references indexed in Scilit:
- Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disordersBehavioural Pharmacology, 2005
- Cannabinoid Modulation of Opiate Reinforcement through the Ventral Striatopallidal PathwayNeuropsychopharmacology, 2005
- The role of endocannabinoid transmission in cocaine addictionPharmacology Biochemistry and Behavior, 2005
- A Critical Interaction between Dopamine D2 Receptors and Endocannabinoids Mediates the Effects of Cocaine on Striatal GABAergic TransmissionNeuropsychopharmacology, 2004
- SR-141716A-induced stimulation of locomotor activityPharmacology Biochemistry and Behavior, 2002
- Cocaine and Amphetamine Depress Striatal GABAergic Synaptic Transmission through D2 Dopamine ReceptorsNeuropsychopharmacology, 2002
- Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats.Life Sciences, 2001
- Involvement of central cannabinoid (CB 1 ) receptors in the establishment of place conditioning in ratsPsychopharmacology, 1998
- A Critique of Fixed and Progressive Ratio Schedules Used to Examine the Neural Substrates of Drug ReinforcementPharmacology Biochemistry and Behavior, 1997
- Microinjections of phencyclidine (PCP) and related drugs into nucleus accumbens shell potentiate medial forebrain bundle brain stimulation rewardPsychopharmacology, 1996